Skip to content

Odyssey Health, Inc.: 10-Q filed 2025-03-14

What Odyssey Health, Inc. reported in its quarterly report filed 2025-03-14 (fiscal Q2 2025): 28 published measures, 85 facts as tagged in accession 0001683168-25-001617.

This filing

Form
10-Q (quarterly report)
Filed
2025-03-14
Fiscal period
fiscal Q2 2025
Accession
0001683168-25-001617 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Odyssey Health, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-01-31266,866USD
At 2024-07-31586,146USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-01-31-6,462,820USD
At 2024-10-31-6,278,825USD
At 2024-07-31-5,333,749USD
At 2024-01-318,670,412USD
At 2023-10-31-6,218,273USD
At 2023-07-31-6,155,929USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-01-317,187USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-11-01 to 2025-01-31-220,126USD92
2024-08-01 to 2025-01-31-1,239,032USD184
2024-08-01 to 2024-10-31-1,018,906USD92
2023-11-01 to 2024-01-3113,277,566USD92
2023-08-01 to 2024-01-3112,739,531USD184
2023-08-01 to 2023-10-31-538,035USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-08-01 to 2025-01-31-295,192USD184
2023-08-01 to 2024-01-31-967,442USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-08-01 to 2025-01-31300,000USD184
2023-08-01 to 2024-01-3196,717USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-08-01 to 2025-01-310USD184
2023-08-01 to 2024-01-311,000,000USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-01-31-62,242,178USD
At 2024-07-31-61,003,146USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-11-01 to 2025-01-31104,709,763shares92
2024-08-01 to 2025-01-31104,709,763shares184
2023-11-01 to 2024-01-3191,975,356shares92
2023-08-01 to 2024-01-3189,879,237shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-11-01 to 2025-01-31104,709,763shares92
2024-08-01 to 2025-01-31104,709,763shares184
2023-11-01 to 2024-01-31114,056,382shares92
2023-08-01 to 2024-01-31112,043,228shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-11-01 to 2025-01-310USD/shares92
2024-08-01 to 2025-01-31-0.01USD/shares184
2023-11-01 to 2024-01-310.14USD/shares92
2023-08-01 to 2024-01-310.14USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-11-01 to 2025-01-310USD/shares92
2024-08-01 to 2025-01-31-0.01USD/shares184
2023-11-01 to 2024-01-310.12USD/shares92
2023-08-01 to 2024-01-310.12USD/shares184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-08-01 to 2025-01-3196,618USD184
2023-08-01 to 2024-01-311,000,119USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-11-01 to 2025-01-31-156,593USD92
2024-08-01 to 2025-01-31-736,020USD184
2023-11-01 to 2024-01-31-1,157,430USD92
2023-08-01 to 2024-01-31-2,004,670USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-01-31108,361USD
At 2024-07-3156,943USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-01-316,729,686USD
At 2024-07-315,919,895USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-01-311,452,794USD
At 2024-07-311,275,996USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-11-01 to 2025-01-310USD92
2024-08-01 to 2025-01-310USD184
2023-11-01 to 2024-01-3142,765USD92
2023-08-01 to 2024-01-3165,766USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-01-3196,709,763shares
At 2024-07-3196,709,763shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-01-317,187USD
At 2024-07-312,379USD
At 2024-01-31166,140USD
At 2023-07-3136,865USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-01-3155,682,648USD
At 2024-07-3155,572,687USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-01-31101,174USD
At 2024-07-3131,939USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-11-01 to 2025-01-31-220,126USD92
2024-08-01 to 2025-01-31-1,239,032USD184
2023-11-01 to 2024-01-3113,214,111USD92
2023-08-01 to 2024-01-3112,676,076USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-11-01 to 2025-01-31120,462USD92
2024-08-01 to 2025-01-31639,402USD184
2023-11-01 to 2024-01-31437,274USD92
2023-08-01 to 2024-01-31938,716USD184

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-11-01 to 2025-01-3163,431USD92
2024-08-01 to 2025-01-31132,217USD184
2023-11-01 to 2024-01-31141,601USD92
2023-08-01 to 2024-01-31332,462USD184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-11-01 to 2025-01-31-102USD92
2024-08-01 to 2025-01-31-97USD184
2023-11-01 to 2024-01-318,890USD92
2023-08-01 to 2024-01-318,956USD184

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-08-01 to 2025-01-311,758USD184
2023-08-01 to 2024-01-3134,007USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-08-01 to 2025-01-31176,798USD184
2023-08-01 to 2024-01-31-206,404USD184

Inspect the source

Entity
Odyssey Health, Inc. / CIK 0001626644
Captured
2026-09-19T11:19:48.570Z
SEC response SHA-256
1be33e1ca79fd1e1d5399b519a2ef141b4c1191380216b92c135e07a22902f7b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001626644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))